Table 1.
Inclusion criteria for the three study groups.
Table 2.
Signalment, severity of illness, comorbidities, timing of surgery, types and volumes of intravenous fluids received throughout the study, and outcome for patients in each group.
Fig 1.
Etiology and final diagnosis for dogs in each group.
SH: spontaneous hemoperitoneum, NPS: non-pulmonary sepsis, PS: pulmonary sepsis.
Fig 2.
Cumulative fluid volumes in each group: total cumulative fluid volumes (A) and total cumulative fluid volumes divided by duration of inclusion in the study (B).
*, θ: Statistically significant difference (p < 0.05) between the corresponding two groups. HEM: spontaneous hemoperitoneum, NPS: non-pulmonary sepsis, PS: pulmonary sepsis.
Fig 3.
Mean hyaluronic acid concentration in time in patients with spontaneous hemoperitoneum (A), non-pulmonary sepsis (B), pulmonary sepsis (C), and all groups combined (D).
The bolded line represents the mean value of hyaluronic acid and the underlying shadow represents the 95% confidence interval. *, θ: Statistically significant difference (p < 0.05) between the corresponding time points.
Table 3.
Mean hyaluronic acid concentration in each group at each time point.
Table 4.
Mean IL-6 concentration in each group at each time point.
Fig 4.
Predicted mean hyaluronic acid concentration at T0 based on IL-6 concentration at T0 (A) and APPLEfast score at T0 (B).
HA concentrations were back-transformed from the logarithmic transformation. The concentration of IL-6, the APPLEfast score, and the administration of IV fluids before hospital admission have a significant positive effect on HA concentration at T0 (p = 0.026, p = 0.015, and p = 0.015, respectively). HA: hyaluronic acid, IL-6: interleukin-6.
Fig 5.
Predicted mean hyaluronic acid as a function of cumulative fluid volume for time points T2 to T48.
HA concentrations were back-transformed from the logarithmic transformation. The cumulative fluid volume has a significant positive effect on HA from T2 to T48 (p = 0.0002). HA = hyaluronic acid.